Why Have Revance Therapeutics Shares More Than Doubled Since The February IPO?
- Injectable Botulinum toxin treatments are the most popular cosmetic procedure in the United States and the rest of the world.
- A topical Botulinum toxin treatment could overcome consumer concerns about injectable Botulinum toxin, representing a potential billion dollar market opportunity.
- Revance’s TransMTS technology could deliver other molecules across the skin that currently require injections.
- Since its initial public offering (IPO) on February 6, 2014, Revance Therapeutics has more than doubled.